TSBX

Turnstone Biologics Corp. (TSBX) | Rumor.io

Turnstone Biologics

TSBX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about TSBX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 27

Turnstone Biologics Corp. ($TSBX) has agreed to a merger with XOMA Royalty Corp. at $0.34 per share in cash, plus a contingent value right (CVR) with a potential payout of up to $1.11 million.
The merger is expected to close in August 2025, with XOMA Royalty to commence a tender offer by July 11, 2025, to acquire all outstanding shares of Turnstone common stock.
The deal includes a CVR with a potential payout of up to $1.11 million, with holders entitled to receive their portion of the amount equal to contingent payments relating to tax receivables and a lease security deposit, minus any net cash shortfall.

Generated by AI

Sentiment

Of the messages about TSBX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.57% +5.03
Bearish	—	—	—	9.43% -5.03

Bullish· Nov 6

$TSBX has the potential to be an absolute beast with its tumour-eating cancer treatment process to be presented soon, leading to a boom in its stock price.
Institutional accumulation is ahead of the clinical data presentation, indicating a strong buying interest in $TSBX, which could result in a significant move.
$TSBX is showing consistent larger highs and larger lows, with notable volume signaling increased buying interest, and is poised to reach $1 with its current momentum.

Bearish· Aug 15

$TSBX's cash reserves are not sufficient to fund operations beyond Q3, casting doubt on the company's ability to continue as a going concern.
The company's reported positive initial data from a clinical trial may not be enough to offset concerns about its financial situation and lack of a business partner.
The stock's price drop is largely due to the company's expected operating losses and negative cash flows, which may lead to significant dilution in the future.

Generated by AI

Topics

Of the messages about TSBX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	86.49%
Controversies	—	—	—	9.46%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	4.05%

Jun 27

Turnstone Biologics Corp. ($TSBX) has entered into a definitive merger agreement with XOMA Royalty Corporation ($XOMA) to be acquired for $0.34 in cash per share plus one non-transferable contingent value right.
The merger transaction is expected to close in August 2025, with XOMA Royalty commencing a tender offer by July 11, 2025, to acquire all outstanding shares of Turnstone common stock.
Approximately 25.2% of Turnstone common stock has been signed in support agreements to tender their shares in the offer, with the merger transaction expected to close in August 2025.

Generated by AI

Community

Of the messages about TSBX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	15.06%
Newcomers	—	—	—	84.94%

Jun 27

The acquisition of Turnstone Biologics Corp. by XOMA Royalty Corporation is for $0.34 in cash per share, with the possibility of a contingent value right (CVR) payout.
The merger agreement between XOMA Royalty Corporation and Turnstone Biologics Corp. is expected to close in August 2025, with an asset sale yielding $3 million.
Some investors are considering $TSBX as a trading opportunity, with the acquisition price being $0.34 in cash plus CVR, and the current price being $0.35, with a perceived low downside risk.

Generated by AI

Also Discussed

Investors talking about TSBX also mention

#	Name	Attention
1	Rallybio Corp.RLYB	0%0
2	TERN - Terns Pharmaceuticals, Inc.	——
3	KRON - Kronos Bio, Inc.	——
4	Cabaletta Bio Inc.CABA	0%0
5	SGE - Strong Global Entertainment, Inc.	——
6	Reborn Coffee, Inc.REBN	0%+0
7	Alternus Clean Energy, Inc.ALCE	0%new
8	Revelation Biosciences Inc.REVB	0%0
9	LUXH - LuxUrban Hotels Inc.	——
10	VS Media Holdings Limited Class A Ordinary SharesVSME	0%+0